Overview
The pharmaceutical industry has paid over $50 billion in fraud settlements since 2000, making it one of the most criminally convicted industries in history. Every major pharmaceutical company has pleaded guilty to criminal charges or paid massive fraud settlements - many multiple times.
These convictions involve systematic fraud including: promoting drugs for unapproved uses, hiding safety data, bribing doctors, defrauding Medicare and Medicaid, and making false claims about drug efficacy. Despite the scale of this criminal activity, executives almost never face personal consequences.
The fines, while appearing large, typically represent a fraction of the profits made from the illegal activity. This creates a business model where crime pays: break the law, make billions, pay millions in fines, repeat.
"The companies seem to treat these fines as just another cost of doing business. When you can make $10 billion from illegal activity and pay a $2 billion fine, that's a pretty good return on investment."
- Healthcare Fraud Prosecutor
Major Fraud Settlements
These are the largest pharmaceutical fraud settlements in U.S. history, all documented in federal court records.
GlaxoSmithKline - $3 Billion
2012
Largest healthcare fraud settlement in history at the time. Pled guilty to promoting Paxil and Wellbutrin for unapproved uses, failing to report safety data on Avandia (linked to heart attacks), and bribing doctors.
Pfizer - $2.3 Billion
2009
Largest criminal fine in U.S. history at the time. Pled guilty to illegally promoting Bextra for uses not approved as safe by FDA. Also resolved allegations regarding Geodon, Zyvox, and Lyrica.
Johnson & Johnson - $2.2 Billion
2013
Pled guilty to illegally marketing antipsychotic drug Risperdal for elderly dementia patients (unapproved use) and paying kickbacks to physicians and nursing homes.
Abbott Laboratories - $1.5 Billion
2012
Pled guilty to illegally promoting Depakote for dementia and schizophrenia (unapproved uses). Internal documents showed company knew drug was ineffective for these uses.
Eli Lilly - $1.4 Billion
2009
Pled guilty to illegally promoting Zyprexa for dementia in elderly patients. Drug was linked to diabetes and weight gain. Company concealed these risks.
Merck - $950 Million
2011
Settled charges of illegally promoting Vioxx before FDA approval, making false statements about cardiovascular safety, and paying kickbacks to doctors.
Repeat Offenders
Many pharmaceutical companies have been convicted multiple times, demonstrating that fines alone do not deter criminal behavior.
Pfizer's Record
$2.3 Billion Settlement
Bextra and other drugs illegally marketed. Largest criminal fine in U.S. history at the time.
$430 Million Settlement
Neurontin illegally marketed for unapproved uses including bipolar disorder and pain.
$49 Million Settlement
Lipitor overcharging of Medicaid.
GlaxoSmithKline's Record
$3 Billion Settlement
Multiple drugs illegally marketed, safety data hidden, doctors bribed.
$250 Million Settlement
Manufacturing defects at Puerto Rico plant.
$750 Million Settlement
Manufacturing defects and contaminated drugs.
Pattern of Behavior
The same companies commit fraud repeatedly, pay fines, and continue operating unchanged. This pattern demonstrates that current enforcement is insufficient to deter criminal behavior in the pharmaceutical industry.
Types of Pharmaceutical Fraud
Off-Label Marketing
The most common type of pharmaceutical fraud. While doctors can prescribe drugs for any use, companies cannot legally promote drugs for uses not approved by the FDA as safe and effective.
- Promoting drugs for age groups not studied (e.g., children)
- Promoting for conditions without efficacy data
- Promoting at higher doses than approved
- Using sales reps, medical education, and paid speakers to spread off-label messages
Kickbacks and Bribery
- Paying doctors to prescribe specific drugs
- "Consulting fees" and "speaking fees" as disguised payments
- Free trips, meals, gifts to physicians
- Payments to nursing homes to use specific medications
Safety Data Concealment
- Hiding negative trial results from FDA
- Not publishing studies showing harm
- Ghost-writing studies to minimize risks
- Delaying reports of adverse events
Medicare/Medicaid Fraud
- Overcharging government programs
- Billing for services not rendered
- Falsifying "best price" data
- Illegal switching to more expensive drugs
No Executives Jailed
Despite billions in criminal fines and documented fraud that harmed patients, pharmaceutical executives almost never face personal consequences.
Corporate Accountability Gap
- Corporations plead guilty, but individuals are not charged
- Fines are paid by shareholders, not executives
- Executive bonuses often continue despite fraud
- "Deferred prosecution agreements" allow companies to avoid trial
- "Corporate integrity agreements" are rarely enforced
Comparison to Other Crimes
An individual caught selling drugs without a license faces years in prison. A corporation that illegally sells drugs to millions, conceals safety data, and causes deaths pays a fine. No executive loses their freedom.
"When companies are caught breaking the law, they pay a fine and promise not to do it again. When they break the law again, they pay another fine. Where are the criminal prosecutions? Where are the prison sentences?"
- Senator Elizabeth Warren, Senate Hearing 2015
The Sackler Exception
The Sackler family, owners of Purdue Pharma (maker of OxyContin), faced personal lawsuits for their role in the opioid epidemic. While they paid billions in settlements, they did not face criminal charges and retained much of their wealth through complex corporate restructuring.
Fines as Cost of Business
When fines are smaller than profits from illegal activity, breaking the law becomes a rational business decision.
Profit vs. Penalty Analysis
| Drug | Sales During Fraud | Fine |
|---|---|---|
| Neurontin (Pfizer) | $2.7 billion | $430 million |
| Risperdal (J&J) | $30+ billion total | $2.2 billion |
| Zyprexa (Lilly) | $36+ billion total | $1.4 billion |
Rational Crime
If a company makes $10 billion from illegal activity and pays a $2 billion fine, they have still profited $8 billion from breaking the law. This creates an incentive structure that rewards fraud.
Documentary Evidence
DOJ Press Releases
Department of Justice announcements of all major pharmaceutical fraud settlements.
Justice.govCorporate Integrity Agreements
HHS Office of Inspector General maintains database of all corporate integrity agreements with pharmaceutical companies.
OIG.HHS.govPublic Citizen Violation Tracker
Comprehensive database of corporate misconduct by major pharmaceutical companies.
ViolationTracker.orgSenate Finance Committee Reports
Congressional investigations into pharmaceutical company practices and fraud.
Congressional Record